shadow_tr

Faculty

Tina K ThetiTina K. Thethi, MD, MPH

Tulane University School of Medicine
Assistant Professor, Department of Medicine, Section of Endocrinology
E-mail: tthethi@tulane.edu

Obesity, diabetes, complications of diabetes and biomarkers of kidney disease


Biography

Dr. Thethi’s research interests’ center around insulin resistance, obesity, diabetes mellitus (both type 1 and 2) and complications of diabetes. One aspect of type 1 diabetes that Dr. Thethi has investigated and documented is the loss of glycemic control over time when the pump infusion line is left in place beyond the current recommendations. Dr. Thethi has particular interest in biomarkers of kidney disease, including urinary free light chains. Her other areas of interest lie in the racial and gender differences in the endocannabinoid system, role of immunosuppressive agents in the pathogenesis of the insulin resistance in transplant patients, endothelial dysfunction along with cardiovascular disease in type 2 diabetes mellitus.

Ongoing research projects related to diabetes and obesity

  1. Effect of renin-angiotensin-system blockade on urinary free light chain excretion in patients with type 2 diabetes mellitus. The purpose of the research study was to get pilot data on the effect of renin-angiotensin system blockade on urinary free light chain excretion in patients with type 2 diabetes mellitus.
  2. Protocol #NN9535-3744 -SUSTAIN™ 6 - Long term outcomes A long-term, randomized, double-blind, placebo-controlled, multinational, multi-centre trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes.
  3. Protocol # ITCA 650-CLP-103 – Exenatide in DUROS® Device A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients with Type 2 Diabetes
  4. Protocol # ITCA 650-CLP-107 – Exenatide in DUROS® Device A Randomized, Multicenter Study to Evaluate Cardiovascular Outcomes with ITCA 650 in Patients Treated with Standard of Care for Type 2 Diabetes
  5. Relevance of Urinary Renin, Prorenin, and TGF-beta in patients with diabetes and hypertension: Impact of Gender. The long term goal of the proposed study is to establish the importance of urinary excretion of renin, Prorenin, and TGF‐β1 as contributors of the progression of renal disease in patients with diabetes and to elucidate how this is altered by hypertension. This study will also examine sex disparities in the urinary excretion of renin, Prorenin, and TGF‐β1 in non-diabetic and diabetic patients with or without hypertension.
  6. A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events (LEADER). The primary objective of this trial is to assess the effect of treatment with Liraglutide compared to placebo for at least 3.5 year and up to 5 years on the incidence of cardiovascular events in adults with type 2 diabetes that are at high risk for cardiovascular events.
  7. Glycemia Reduction Approaches for Diabetes: A Comparative Effectiveness Study (GRADE)
    The purpose of GRADE is to investigate which therapies for type 2 diabetes mellitus work better in individuals with particular characteristics and to determine the differential effects of various therapeutic approaches on the physiology of glucose metabolism. The study design will compare five major diabetes drug combinations and examine two different treatment strategies in a single trial.

Other Links

Tulane http://tulane.edu/som/departments/medicine/endocrinology/thethi_new.cfm
Research Gate
https://www.researchgate.net/profile/Tina_Thethi/?ev=prf_high
PubMed http://www.ncbi.nlm.nih.gov/pubmed/?term=thethi%2C+tina

 

« Return to faculty

 

1430 Tulane Ave, New Orleans, LA 70112 504-988-5263 medsch@tulane.edu